- Home
- MIN vs AVIR Comparison
MIN vs AVIR Comparison
Compare MIN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.27
Company Overview
Basic Information| Metric | MIN | AVIR |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.1M | 429.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIN | AVIR |
|---|---|---|
| Price | $2.35 | $5.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 289.0K | 239.0K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $2.78 |
| 52 Week High | $2.68 | $6.45 |
Technical Indicators
Market Signals| Indicator | MIN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.23 | N/A |
| Support Level | $2.31 | N/A |
| Resistance Level | $2.48 | N/A |
| Average True Range (ATR) | 0.02 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 30.77 | 0.00 |
Price Performance
Historical Comparison MIN
AVIR
About MIN MFS Intermediate Income Trust
Aberdeen Intermediate Income Fund is a diversified, closed-end fixed-income management investment company. The fund's investment objective is to seek high current income, but may also consider capital appreciation.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.